Kynmobi

Apomorphine Hydrochloride Hemihydrate, the active ingredient in Kynmobi, is a dopamine agonist presented as a sublingual film for sublingual use. It is indicated for the rapid relief of off episodes in Parkinson's disease, providing non‑selective stimulation of central dopamine receptors to improve motor function during fluctuations.

GNH USA supplies Kynmobi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution channels that meet EU regulatory standards. The company ensures product integrity through rigorous quality control and provides logistical support for global procurement.

Kynmobi is a dopamine agonist used to manage motor fluctuations in Parkinson's disease.

Off episodes: rapid reversal of motor fluctuations in Parkinson's disease Parkinson's disease: improves mobility during off periods Motor fluctuations: provides sublingual dopaminergic support to reduce symptom gaps

Common Side Effects: - Nausea - Vomiting - Dizziness or light‑headedness - Orthostatic hypotension - Headache - Dry mouth

Serious or Rare Side Effects: - Severe hypotension or syncope - Neuroleptic malignant syndrome‑like reaction - Cardiac arrhythmias - Persistent severe nausea/vomiting leading to dehydration - Severe psychiatric disturbances such as hallucinations

Before initiating therapy, evaluate cardiovascular status and monitor for severe hypotension.

- Cardiovascular assessment: evaluate for severe hypotension before initiating therapy - Avoid use in patients with known hypersensitivity to apomorphine or formulation components - Monitor for orthostatic dizziness: advise patients to rise slowly - Caution in patients with psychiatric disorders: may exacerbate hallucinations - Pregnancy and lactation: safety not established; use only if benefit outweighs risk - Store at room temperature: keep in original packaging, protect from moisture and light

Apomorphine may interact with several drug classes; careful review is required.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis - Antipsychotics (dopamine antagonists): antagonize therapeutic effect - Antihypertensive agents: additive hypotensive effect - Other dopamine agonists: increased risk of side effects - Serotonergic drugs: potential serotonin syndrome

Moderate Interactions (Monitor Closely): - CYP450 inhibitors: may increase plasma levels - Alcohol: may enhance dizziness and hypotension - Beta‑blockers: may mask tachycardia - Anticholinergics: may affect gastrointestinal motility - Diuretics: may exacerbate orthostatic hypotension